Approximately 70% of medical devices entering the U.S. market follow the 510(k) pathway. The predicate device you select determines whether your submission demonstrates substantial equivalence or triggers a Not Substantially Equivalent (NSE) determination, which is a far more costly regulatory route. This article covers what it takes to select a strong predicate, search FDA databases effectively, and avoid the mistakes that delay clearance.
In this article, you’ll learn:
- The criteria that distinguish a cleared device from a rejected one – and why manufacturers frequently get this wrong
- A structured database search sequence for locating strong predicate candidates
- The two-part test that the FDA applies when evaluating substantial equivalence
- Four best practices from the FDA’s 2023 draft guidance that can strengthen or weaken your predicate choice
- The predicate strategy that FDA explicitly calls “inconsistent with the 510(k) regulatory standard.”
What Qualifies as a Predicate Device
Not every similar device on the market qualifies as a predicate. The FDA limits eligible predicates to legally marketed devices that fall into one of three categories.
| Predicate Type | Description |
|---|---|
| 510(k)-Cleared Device | A device cleared through a prior 510(k) submission |
| Preamendments Device | A device legally marketed in the U.S. before May 28, 1976, and unchanged since |
| De Novo-Classified Device | A device originally classified through the De Novo pathway |
A predicate cannot be a device that is or was in violation of the Federal Food, Drug, and Cosmetic (FD&C) Act. Manufacturers may use a device that is no longer being marketed in the U.S., provided it meets the legal marketing criteria above.
Most manufacturers select a recently cleared 510(k) device as their primary predicate. Recent clearances use current consensus standards and FDA guidance, which makes equivalence comparisons more direct and easier for reviewers to evaluate.
How to Search for Predicate Candidates
The FDA 510(k) database is the primary tool for predicate research. Searching by product code, the FDA-assigned three-letter “procode” returns the most relevant results and filters out devices in unrelated categories.
Follow this search sequence:
- Identify your device’s classification in the FDA Product Code Classification Database to confirm your product code.
- Search the 510(k) database by product code to locate cleared devices in your category.
- Review post-market data for each candidate using the FDA’s MAUDE database and Medical Device Recalls Database.
| Search Tool | Purpose |
|---|---|
| Product Code Classification Database | Confirms device classification and procode |
| FDA 510(k) Database | Locates cleared devices by procode, trade name, or manufacturer name |
| MAUDE Database | Surfaces the adverse event history for predicate candidates |
| Medical Device Recalls Database | Flags design-related recalls that disqualify a predicate |
The 510(k) database reflects only original application data. It does not update to show current ownership or trade name changes. If an initial search returns no results, try alternate manufacturer name formats.
Demonstrating Substantial Equivalence
FDA evaluates substantial equivalence through a two-part test. Your device must share the same intended use as the predicate. Then it must either share the same technological characteristics or have technological differences that do not raise different questions of safety and effectiveness.
| Equivalence Criterion | What the FDA Evaluates |
|---|---|
| Intended Use | Same overall medical purpose; differences in indication or patient population do not automatically mean a different intended use |
| Same Technological Characteristics | Technical features – including design, materials, and energy – align with the predicate |
| Different Technological Characteristics | Differences exist, but do not introduce new or different risk questions |
When your device has different technological characteristics, the FDA may require performance data to confirm that your device performs at least as well as the predicate. Accepted data types include:
- Non-clinical bench performance testing
- Electromagnetic compatibility (EMC) results
- Biocompatibility evaluations
- Software validation documentation
FDA’s 2023 Draft Best Practices for Predicate Selection
In September 2023, the FDA issued draft guidance (Docket FDA-2023-D-3134) recommending four best practices for selecting a predicate. The guidance aims to modernize the 510(k) program and discourage reliance on outdated or problematic predicates.
| Best Practice | What It Means |
|---|---|
| Cleared using well-established methods | FDA reviewed the predicate against current consensus standards or FDA guidance documents |
| Meets or exceeds safety and performance expectations | The predicate has not accumulated high rates of adverse events or malfunctions post-clearance |
| Free of unmitigated use- or design-related safety issues | Known usability or design hazards have been addressed |
| No design-related recalls | The predicate was not withdrawn from the market due to a design defect |
When multiple valid predicates exist, FDA expects manufacturers to justify their selection. A strong predicate minimizes the documentation burden and reduces the likelihood of a Request for Additional Information (RAI) during review.
Predicate Pitfalls to Avoid
Understanding common pitfalls in predicate selection is critical to avoiding delays and regulatory setbacks in the 510(k) process.
Using a Split Predicate
FDA explicitly states that split predicates are inconsistent with the 510(k) regulatory standard. A split predicate occurs when a manufacturer claims intended use from one device and technological characteristics from a different, unrelated device. FDA rejects this approach. Every predicate you cite must share the same intended use as your device.
Selecting a Predicate with Active Safety Concerns
Predicates with elevated adverse event rates in MAUDE, or those subject to design-related recalls, signal a weak comparison. FDA’s 2023 draft guidance identifies these as poor candidates. Citing one invites additional scrutiny and may require clinical data to bridge the equivalence gap.
Skipping the Pre-Submission Meeting
A Pre-Submission (Q-Sub) consultation lets you present your predicate strategy to FDA reviewers before filing. This step surfaces alignment issues early – before they result in NSE determinations or RAI cycles that extend your timeline. There is no standard fee for a Q-Sub consultation.
Get Your 510(k) Testing Right the First Time
Predicate selection determines the scope of testing data your submission requires. MiCOM Labs provides A2LA-accredited testing under ISO/IEC 17025 (Certificate #2381.01), producing test reports accepted by FDA reviewers. The MiTest® platform delivers real-time test monitoring and automated reporting, so you have performance data available before final reports are complete.
Contact MiCOM Labs to discuss your device specifications and testing requirements. Receive a detailed proposal outlining applicable standards, testing scope, and regulatory timelines.